Health care companies in the US have had to shell out to fund Obamacare, while mega-cap pharmaceutical companies have been navigating patent cliffs in recent years. AXA Framlington's health care manager Gemma Game explains some of the reasons why investors should stay positive on the sector.
US healthcare is one of the most interesting sectors to observe, as since the inauguration of President Obama uncertainty about the ramifications of healthcare system reform has weighed on the many industries that make up the sector. Financial strain Companies across the sector have been subjected to additional taxes and fees to pay for the ambitious programme, which aims to address the estimated 48 million US patients with no access to affordable healthcare insurance. Meanwhile, the mega-cap pharmaceutical companies have been posting pedestrian growth as they navigate their way o...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
